Research Paper

Diagnostic Performance Analysis of the Point-of-Care Bilistick System in Identifying Severe Neonatal Hyperbilirubinemia by a Multi-Country Approach

Chiara Greco a, Iman F. Iskander b, Salma Z. El Houchi b, Rinawati Rohsiswatmo c, Lily Rundjan c, Williams N. Ogala d, Akinyemi O.D. Ofakunrin e, Luciano Moccia f, Nguyen Thi Xuan Hoig g, Giorgio Bedogni h, Claudio Tiribelli a,h, Carlos D. Coda Zabetta a,e, on behalf of the study team 1

a Bilimetrix s.r.l., Area Science Park, 34149 Trieste, Italy
b Department of Pediatrics, Cairo University Children Hospital, Cairo, Egypt
c Neonatology Division, Child Health Department, Cipto Mangunkusumo Hospital - University of Indonesia, Jakarta, Indonesia
d Neonatal Unit, Department of Paediatrics, Ahmadu Bello University/Teaching Hospital, Zaria, Nigeria
e Department of Paediatrics, University of Jos/ Jos University Teaching Hospital, Jos, Nigeria
f Day One Health, California, USA
g Day One Health, Hanoi, Viet Nam
h Fondazione Italiana Fegato-Onlus, Area Science Park, 34149 Trieste, Italy

ABSTRACT

Importance: The real prevalence and clinical burden of severe neonatal jaundice are undefined due to difficulties in measuring total serum bilirubin (TSB) outside secondary and tertiary clinical centers.

Objective: To assess the diagnostic performance of the point-of-care Bilistick System (BS) in identifying neonatal jaundice patients requiring treatment.

Design: Between April 2015 and November 2016, 1911 neonates, were recruited to participate in the study. Blood samples were simultaneously collected for the TSB determination by BS and by hospital laboratory (Lab). Data were collected and sent to the Bilimetrix headquarter in Trieste where statistical analysis was performed. Newborns with neonatal jaundice were treated with phototherapy according to each center’s guidelines.

Setting: 17 hospitals from Nigeria, Egypt, Indonesia, and Viet Nam.

Participants: 1911 newborns were included, of which 1458 (76.3%) fulfilled the inclusion criteria.

Results: TSB level measured by BS agreed (p < 0.0001) with the lab result in all four countries. The diagnostic performance of BS showed a positive predictive value (PPV) of 92.5% and a negative predictive value (NPV) of 92.8%.

Conclusions and Relevance: BS is a reliable system to detect neonatal jaundice over a wide range of bilirubin levels. Since Bilistick is a point-of-care test, its use may provide appropriate and timely identification of jaundiced newborns requiring treatment.

© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Keywords: Neonatal jaundice, Severe hyperbilirubinemia, Neonatal screening, Bilirubin, Bilistick System, Point-of-care system, Diagnostic accuracy study, STARD, Low-medium income countries

1. Introduction

A common condition in newborn infants is neonatal jaundice (NNJ) [1] characterized by high levels of Total Serum Bilirubin (TSB) concentrations. Under normal conditions, it resolves without treatment and with a benign outcome. International medical guidelines [2–5] however recommend assessing the risk of developing severe hyperbilirubinemia in each newborn [6, 7] in order to identify those who need treatment to prevent development of acute bilirubin encephalopathy (ABE) and its long-term consequences, kernicterus spectrum disorders (KSD) [8–10].

The number of cases of severe hyperbilirubinemia in high-income countries (HICs) has decreased drastically since the implementation of these guidelines [11]. On the contrary, several studies have shown that severe hyperbilirubinemia remains a life-threatening condition in many areas of the world, especially low middle-income countries (LMICs), though the real dimension of the problem is largely unknown [12].
Research in context

Evidence before this study

Severe neonatal jaundice remains in low-income settings a life-threatening condition, and the real dimension of the problem is largely unknown. We searched peer reviewed articles in PubMed using the search terms “neonatal jaundice” OR “hyperbilirubinemia” OR “acute bilirubin encephalopathy” OR “kernicterus spectrum disorders” OR “kernicterus” OR “cerebral palsy” AND “epidemiology” OR “prevalence” OR “frequency” OR “surveillance” OR “screening” OR “low income” OR “resource poor” OR “mortality”. We only included English-language studies. Although we found many recent studies that have reported important data on severe hyperbilirubinemia, ABE, and CBE in poor resource countries, the real prevalence and clinical burden of severe neonatal jaundice remain still undefined mainly because the information reported from LMICs are heterogeneous and largely drawn from tertiary hospitals. In the secondary and primary levels of health care, the dimension of the problem remains unknown due to the lack of affordable and reliable tools to diagnose of NNJ. This inability to promptly estimate total bilirubin level is a major obstacle to carry out an appropriate and timely treatment and eliminate this tragic and preventable life-threatening condition.

Added value of this study

Our prospective and multicenter cohort study involved 17 hospitals from Nigeria, Egypt, Indonesia, and Vietnam between April 2015 and November 2016. We compared total serum bilirubin (TSB) assessed in clinical laboratory (Lab) with that measured by the Bilistick System (BS) a low-cost point-of-care assay. Our objective was to validate the performance of BS on measuring TSB and determining the prevalence of neonatal jaundice and need of treatment in real-world condition across different countries.

Implications of all the available evidence

The present study reveals the BS as a reliable point-of-care assay to detect neonatal jaundice over a wide range of bilirubin levels and determine appropriate treatment for jaundiced newborns to prevent development of acute bilirubin encephalopathy and its consequences.

In many LMICs there is paucity of accessible timely effective laboratory support services to promptly estimate bilirubin levels in jaundiced newborns [13], especially in the secondary and primary levels of health care. In many instances, results are obtained ≥24 h after testing leading to unnecessary delays in needed treatment, increasing the possibility of the patient needing an exchange transfusion (ET) or developing ABE. The introduction of inexpensive, easy to use, accurate point-of-care devices to measure bilirubin TSB that allow rapid, appropriate treatment of severe NNJ is an essential bridge in eliminating a major gap treatment of this disease problem [14].

The Bilistick System (Blimetrix srl, Italy - BS) is a low cost point-of-care (POC) system that can be used as a screening diagnostic tool to estimate the TSB concentration, simplifying the triage of newborns and the evaluation of hyperbilirubinemia risk following discharge from birthing centers [15, 16]. One of the main advantages of the BS is the ability to carry the instrument where the TSB needs to be performed, i.e. physician offices, rural healthcare settings including village clinics and even homes [17–19].

The aim of the study was to test the diagnostic accuracy of the BS for the evaluation of the TSB concentration on whole blood of newborn infants in Africa and Asia, comparing it to the laboratory-based assay.

2. Methods

The study was conducted according to the STARD (Standards for the Reporting of Diagnostic Accuracy Studies) guidelines [20, 21]. We performed a prospective, multicenter, cohort study in 17 medical centers serving ethnically different populations distributed in Africa (1 in Egypt and 3 in Nigeria) and in Asia (7 in Indonesia and 6 in Viet Nam), for a total period of 20 months from April 1st, 2015 through November 30th, 2016 (eTable 1 in the Supplement).

Samples and clinical data were collected from consecutive inborn and outborn (referred) healthy ≥35 weeks gestation age and ≥28 days of age, presenting NNJ at visual examination or ABE signifies thus requiring a laboratory TSB measurement, or when TSB level was measured as part of routine screening [2, 8]. In these newborns, blood samples for TSB assay by both BS and clinical laboratory are simultaneously performed with the same sample for both tests. Age, sex, weight and hematocrit data were also recorded. No formal calculation of sample size was performed.

Participants without TSB result (BS and/or Lab TSB) or demographic data were excluded from the analysis. Other exclusion criteria were hematocrit outside the limits of the machine (<25 or >65%), TSB by Bilistick bilirubin level >40 mg/dL or when technical problems occurred during the test.

The study was approved by each hospital ethics committee, and written or oral informed consent was obtained from the parents of the study newborns.

2.1. Test Methods

The Bilistick System (BS) is a simple, rapid, minimally invasive bilirubin assay that does not require the use of reagents, thus simplifying the process of measurement and reducing costs. It is able to give accurately measures blood samples with bilirubin level ≤ 40 mg/dL and hematocrit (HCT) ranging from 25% to 65%. Operationally, nursing/medical staff collects 25 μL of blood, which is applied on a test strip previously inserted in the Bilistick reader. The strip separates the plasma from corpuscular components of the blood allowing the flow of serum onto the nitrocellulose membrane by capillarity. After saturation of the membrane, the TSB concentration is determined by reflectance spectroscopy within 2 min from loading (Video) [15, 16]. The technical problems which may occur during the testing are due to: 1) the fact that HCT is outside the 25%–65% range; and/or 2) the incorrect handling of sample resulting in haemolysis or undersaturation of the strip membrane or blood coagulation. The Bilistick Reader is programmed to detect when technical problems occur, and the error message appears on display.

The gold standard method for TSB measurement in serum samples is high performance liquid chromatography (HPLC) [22–24]. However, this method is used primarily in research labs due to its technical complexity which renders it unfeasible for clinical use [24, 25]. Clinically, the TSB is usually assessed by the diazo reaction method or direct spectrophotometry [5, 23, 26, 27]. Since these methods were most prevalent around the world, they were taken as reference standards for this study, according to the method available and normally used in each hospital laboratory (Lab) (eTable 1 in the Supplement). Quality controls of laboratory instruments were made according to each hospital’s guidelines and clinical practice. Interlaboratory control was not performed.

The blood samples for Bilistick test and for the laboratory TSB determination were collected simultaneously from the same newborn usually by heel prick: the Bilistick TSB determination was performed immediately by the health personnel while the other sample was sent to the hospital laboratory. In order to prevent bilirubin photo-conversion, standard precautions were used to protect specimens from light exposure. The results obtained were registered for subsequent statistical analysis on a specific format. The laboratory did not know about the result obtained by BS.
2.2. Statistical Analysis

Comparison of TSB results given by Bilistick and laboratory assay were made on each pair of samples. Most variables were not Gaussian-distributed and all are reported as percentiles. Bland–Altman plots of the bias vs. the average were used to evaluate the presence of a proportional bias [28, 29]. Proportional bias was minimal or non-existent as detected by Pearson’s correlation coefficient so that the Bland–Altman limits of agreement (LOA) were calculated. The bias was Gaussian-distributed and is reported as mean and standard deviation. Lin’s concordance coefficient was also calculated to evaluate inter-method agreement.

To investigate the performance of Bilistick in predicting treatment needed, each TSB result was subject to analysis according to treatment threshold table proposed by NICE CG98 full guideline [2]. This table takes into account the bilirubin level and age of the neonate and suggests whether the level of jaundice requires treatment with phototherapy or exchange transfusion. TSB values obtained by laboratory assay were used as control for treatment prediction. Sensitivity, specificity, predictive values, likelihood ratios and ROC Area for the detection of neonates requiring phototherapy by Bilistick were calculated. Statistical analysis was performed using Stata 14.2 (Stata Corporation, College Station, TX, USA).

3. Results

3.1. Participants

Fig. 1 shows how subjects were enrolled and selected in each country. A total of 1911 infants presenting clinically with neonatal jaundice were selected for screening and 1854 were found eligible. A total of 1458 (75.3%) were analyzed. Three hundred and ninety-six subjects were excluded because they lacked TSB measured by Bilistick (n = 130, 33% of excluded), two for TSB >40 mg/dL, 27 for technical reasons, and 237 (60% of excluded) for lack of laboratory data. Out of the remaining 1458 (76·3% of total), 79·5% (n = 119) did not require treatment, 15.5% (n = 226) required phototherapy, and 5.0% (n = 73) required exchange transfusion.

Table 1 reports the population stratified according to geographical origin (continent, country, and hospital), age and outcome of treatment if managed according to NICE CG98 guidelines [2], although actual treatment levels were determined by the treating doctor at each hospital. The majority of the newborns originated from Asia (79.6%) of which 54% from Viet Nam and 46% from Indonesia with the remaining 19.4% from Africa with 11.5% from Nigeria and 8.9% from Egypt.

The demographic characteristics of the neonates are shown in Table 2 expressed as 50th percentile [25th–75th percentile]. The median age of participants was 96 h with a range of 1 h to 28 days, 56% of the newborns were male. TSB mean values (M ± SD) measured by either laboratory or Bilistick was 13.5 ± 5.0 and 13.0 ± 4.8 mg/dL, respectively.

The prevalence of newborns needing treatment according to the NICE CG98 full guideline [2] varied according to country ranging from 15% in Egypt to 26% in Viet Nam (Table 3).

3.2. Test results

The comparison of TSB measured by Bilistick and Lab by Bland–Altman analysis is shown in Fig. 2. Overall the TSB measured by Bilistick

Fig. 1. Diagram reporting flow of participants through the study.
all data are presented as frequency (percentage).

**Table 1**

| Continent | Total (n = 1458) |
|-----------|-----------------|
| Africa | 298 (20.4%) |
| Asia | 1160 (79.6%) |
| State | |
| Egypt | 130 (8.9%) |
| Nigeria | 168 (11.5%) |
| Indonesia | 530 (36.4%) |
| Viet Nam | 630 (43.2%) |

| Hospital | |
|-----------|-----------------|
| Egypt | E-CUCH 130 (8.9%) |
| Nigeria | N-ABUTH 58 (4.0%) |
| Indonesia | N-JUTH 76 (5.2%) |
| Viet Nam | |
| Age (NICE cut-point in hours) | |
| 0 | 26 (1.8%) |
| 6 | 4 (0.3%) |
| 12 | 7 (0.5%) |
| 18 | 11 (0.8%) |
| 24 | 69 (4.7%) |
| 30 | 17 (1.2%) |
| 36 | 33 (2.3%) |
| 42 | 18 (1.2%) |
| 48 | 156 (10.7%) |
| 54 | 29 (2.0%) |
| 60 | 27 (1.9%) |
| 66 | 10 (0.7%) |
| 72 | 254 (17.4%) |
| 78 | 15 (1.0%) |
| 84 | 14 (1.0%) |
| 90 | 10 (0.7%) |
| 96 | 758 (52.0%) |

| Nice management according to laboratory | |
| Not requiring treatment | 1159 (79.5%) |
| Perform phototherapy or ET | 299 (20.5%) |

| Nice management according to Bilistick System | |
| Not requiring treatment | 1230 (84.4%) |
| Perform phototherapy or ET | 228 (15.6%) |

All data are presented as frequency (percentage).

**Table 2**

| Main measurements of the study subjects | Egypt (n = 130) | Nigeria (n = 168) | Asia (n = 530) | Indonesia (n = 630) | Viet Nam (n = 1458) |
|---|---|---|---|---|---|
| Male-to-female ratio | 1.55:1 | 1.30:1 | 1.12:1 | 1.36:1 | 1.27:1 |
| Age (hours) | 144 | [78–195] | 96 | [48–120] | 96 | [72–168] | 96 | [48–110] |
| Weight (g) | 3200 | [3000–3400] | 2900 | [2500–3338] | 2470 | [2111–3070] | 3000 | [2700–3400] |
| Hematocrit (%) | 35.9 | [31.9–40.1] | 44.0 | [40.0–48.0] | 44.1 | [38.3–48.7] | 43.0 | [39.0–48.2] |
| Bilirubin by Laboratory (mg/dL) | 12.9 | [9.7–16.5] | 12.7 | [8.8–15.5] | 13.6 | [10.8–16.9] | 13.4 | [11.2–16.4] |
| Bilirubin by Bilistick (mg/dL) | 11.6 | [8.2–14.5] | 12.0 | [8.2–14.9] | 12.9 | [10.2–16.1] | 12.5 | [10.3–15.7] |

All data are presented as 50th percentile [25th–75th percentile].

was slightly lower than TSB by the laboratory. This difference was constant in the range of TSB measure (1 to 40 mg/dL). The LOA were in Indonesia − 4.0 to 2.3 mg/dL, with a mean ± SD of − 0.8 ± 1.6 mg/dL; in Viet Nam − 5.5 to 3.7 mg/dL, with a mean ± SD of − 0.9 ± 2.3 mg/dL; Egypt − 7.4 to 4.0 mg/dL, with a mean ± SD of − 1.7 ± 2.9 mg/dL, and in Nigeria − 7.5 to 6.0 mg/dL, with a mean ± SD of − 0.8 ± 3.4 mg/dL.

The Lin’s concordance coefficient showed a significant correlation (p < .0001) in Indonesia (0.94 [95% CI 0.93 to 0.95]), in Viet Nam (0.84 [95% CI 0.82 to 0.86]), Egypt (0.80 [95% CI 0.74 to 0.85]) and Nigeria (0.78 [95% CI 0.72 to 0.84]).

The diagnostic accuracy and precision analysis expressed as value [95% CI] of Bilistick to determine the need of phototherapy showed a sensitivity of 70.6% [65.0 to 75.7%], specificity of 98.5% [97.7 to 99.1%], positive predictive value (PPV) of 92.5% [88.3 to 95.6%] and negative predictive value (NPV) of 92.8% [91.3 to 94.2%].

**4. Discussion**

This study is an expansion of the data previously reported in Egypt and includes a large numbers of newborns from 4 different countries in Africa and Asia [16]. As in the previous study, the measurements of TSB were obtained at the same time by Bilistick and laboratory making possible assessment of the performance of the POC BS in different scenarios.

We observed that Bilistick underestimates TSB by about 1 mg/dL and this underestimation is stable over a wide range of TSB values ranging from 1 to 40 mg/dL. This bias may explain the rather low sensitivity (70.6%) we observed. We are now working to remove this systematic error which relates primarily to an error in the calibration curve. Never-the-less we confirmed Bilistick is a valuable and reliable POC device which may be used to determine TSB when laboratory measurements are either unavailable or the results excessively delayed.

The good concordance of results across different nations and continents is a major strength of this study. With all the local limitations and different health care systems, the reproducibility of TSB obtained with Bilistick confirmed that this device works well regardless of the environments where it is used. Based on these results Bilistick may be used in different field studies to define the actual prevalence of severe NNJ worldwide – Information that is still largely unknown [12, 30].

Our study has some limitations which must be considered. The first limitation is the lack of a comparable and standardized method for the measurement of TSB by the laboratories of the different hospitals in the different countries. It is possible that the reproducibility among and within the laboratories was less than ideal. The second limitation of our study is the lack of a priori determination of sample size due to the absence of reliable information of the prevalence of severe neonatal jaundice in most of the countries involved in the study. This preliminary information is essential to calculate positive and negative predictive

 
values. According to the accepted guidelines [31], we did not perform a post-hoc sample size calculation, but we report instead the 95% confidence of the estimates as a means to evaluate their precision. The third limitation is the intrinsic limitation of Bilistick method. Additionally, the threshold maximum hematocrit of 65% (1.8%, eTable 2 in the Supplement) above which there is insufficient amount of plasma in the membrane for bilirubin determination and the skill of the operators in using the Bilistick was problematic in some of the newborns. Most of the newborns excluded for technical reasons (1.4%, eTable 2 in the Supplement) were enrolled early in the study suggesting that operators quickly became comfortable and proficient in the use of the reader and strip suggesting that the Bilistick is user friendly.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.eclinm.2018.06.003.

Abbreviations

| Abbreviation | Description                                      |
|--------------|--------------------------------------------------|
| ABE          | Acute Bilirubin Encephalopathy                   |
| BS           | Bilistick System                                 |
| ET           | Exchange Transfusion                             |
| HCT          | Hematocrit                                       |
| HICs         | High-Income Countries                            |
| HPLC         | High Performance Liquid Chromatography           |
| KSD          | Kernicterus Spectrum Disorders                   |

Table 3

|            | Africa       | Asia         | Total        |
|------------|--------------|--------------|--------------|
|            | Egypt (n = 130) | Nigeria (n = 168) | Indonesia (n = 530) | Viet Nam (n = 630) | Total (n = 1458) |
| Prevalence | Pr(A)        | Pr(A)        | Pr(A)        | Pr(A)        | Pr(A)        |
|            | 15.0%        | 20.0%        | 16.0%        | 26.0%        | 21.0%        |
|            | [9.7%–22.8%] | [14.0%–26.5%]| [13.0%–19.4%]| [22.0%–29.2%]| [18.0%–22.7%]| |
| Sensitivity| Pr(+|A)       | Pr(+|A)       | Pr(+|A)       | Pr(+|A)       | Pr(+|A)       |
|            | 60.0%        | 69.7%        | 67.1%        | 73.9%        | 70.6%        |
|            | [36.1%–80.9%]| [51.3%–84.4%]| [56.0%–76.9%]| [66.4%–80.5%]| [65.6%–75.7%]| |
| Specificity| Pr(−|N)       | Pr(−|N)       | Pr(−|N)       | Pr(−|N)       | Pr(−|N)       |
|            | 98.2%        | 97.8%        | 99.8%        | 97.7%        | 98.5%        |
|            | [93.6%–99.8%]| [93.6%–99.5%]| [98.8%–100%] | [95.8%–98.8%]| [97.7%–99.1%]| |
| ROC Area   | (Sens. + Spec.)/2 | (Sens. + Spec.)/2 | (Sens. + Spec.)/2 | (Sens. + Spec.)/2 | (Sens. + Spec.)/2 |
|            | 0.791        | 0.837        | 0.834        | 0.858        | 0.846        |
|            | [0.680–0.902]| [0.757–0.918]| [0.784–0.884]| [0.823–0.893]| [0.819–0.872]| |
| Likelihood ratio (+) | Pr(+|A)/Pr(+|N) | Pr(+|A)/Pr(+|N) | Pr(+|A)/Pr(+|N) | Pr(+|A)/Pr(+|N) | Pr(+|A)/Pr(+|N) |
|            | 60.0%        | 69.7%        | 67.1%        | 73.9%        | 70.6%        |
|            | [36.1%–80.9%]| [51.3%–84.4%]| [56.0%–76.9%]| [66.4%–80.5%]| [65.6%–75.7%]| |
| Likelihood ratio (−) | Pr(−|A)/Pr(−|N) | Pr(−|A)/Pr(−|N) | Pr(−|A)/Pr(−|N) | Pr(−|A)/Pr(−|N) | Pr(−|A)/Pr(−|N) |
|            | 92.3%        | 98.8%        | 99.8%        | 97.7%        | 98.5%        |
|            | [91.5%–99.9%]| [95.3%–99.8%]| [96.8%–99.8%]| [95.8%–98.8%]| [97.7%–99.1%]| |
| Odds ratio | LR(+)        | LR(+)        | LR(+)        | LR(+)        | LR(+)        |
|            | 33.0         | 34.0         | 31.4         | 31.4         | 34.1         |
|            | [8.0–136.0]  | [10.0–98.2]  | [32.0–298.0] | [31.4–348.0] | [29.8–77.6]  |
| Positive predictive value | Pr(A+) | Pr(A+) | Pr(A+) | Pr(A+) | Pr(A+) |
|            | 85.7%        | 85.7%        | 85.7%        | 85.7%        | 85.7%        |
|            | [57.2%–98.2%]| [69.8%–97.6%]| [69.8%–97.6%]| [69.8%–97.6%]| [69.8%–97.6%]| |
| Negative predictive value | Pr(N−) | Pr(N−) | Pr(N−) | Pr(N−) | Pr(N−) |
|            | 93.1%        | 93.1%        | 93.1%        | 93.1%        | 93.1%        |
|            | [86.9%–97.0%]| [87.4%–96.6%]| [87.4%–96.6%]| [87.4%–96.6%]| [87.4%–96.6%]| |
| All data are presented as value [95% Confidence Interval].
Additional Members of the Study Team accountable for all aspect of the work. All authors approved the other authors of the study team participated in the collection of the data. supervised data collection and critically reviewed the manuscript. C.D.C.Z. conceptualized and designed the study, coordinated and conceptualized and designed the study and critically reviewed the manuscript. C.T. Nam and reviewed and revised the manuscript. G.B. designed and carried out the statistical analyses and reviewed and revised the manuscript. C.R. and L.R. supervised data collection in Nigeria and reviewed and revised the manuscript. W.N.O. reviewed and revised the manuscript. R.R. and L.R. supervised data collection in Nigeria and reviewed and revised the manuscript. I.F.I. and S.Z.E.H. supervised data collection in Egypt and reviewed and revised the manuscript. F.B. designed and carried out the statistical analyses and reviewed and revised the manuscript. C.G. conceptualized and designed the study, carried out the initial manuscript as submitted and agree to be accountable for all aspect of the work.

Contributors

C.G. conceptualized and designed the study, carried out the initial analyses, drafted the initial manuscript and reviewed and revised the manuscript. I.F.I. and S.Z.E.H. supervised data collection in Egypt and reviewed and revised the manuscript. R.R. and L.R. supervised data collection in Indonesia and reviewed and revised the manuscript. W.N.O. and A.O.D.O. supervised data collection in Nigeria and reviewed and revised the manuscript. L.M. and N.T.X.H. supervised data collection in Viet Nam and reviewed and revised the manuscript. G.B. designed and carried out the statistical analyses and reviewed and revised the manuscript. C.T. conceptualized and designed the study and critically reviewed the manuscript. C.D.C.Z. conceptualized and designed the study, coordinated and supervised data collection and critically reviewed the manuscript. All the other authors of the study team participated in the collection of the data. All authors approved the final manuscript as submitted and agree to be accountable for all aspect of the work.

Acknowledgment

The studies performed in Nigeria and Indonesia were possible through the generous support of the Saving Lives at Birth partners: the United States Agency for International Development (USAID), the Government of Norway, the Bill & Melinda Gates Foundation, Grand Challenges Canada, and the UK Government (FOG award N° AID-OAA-F-13-00072). The study in Viet Nam was realized with the contribution of Eric Hemel and Barbara Morgen (Scarsdale, USA), private donors of the East meets West Foundation (Oakland, CA, USA).

NIGERIA:

- Stephen Oguche Department of Paediatrics, University of Jos, Jos University Teaching Hospital, Jos, Nigeria
- Christian Isichei Department of Chemical Pathology, University of Jos, Jos University Teaching Hospital, Jos, Nigeria
- Bose O. Toma Department of Paediatrics, University of Jos, Jos University Teaching Hospital, Jos, Nigeria
- David D. Shwe Department of Paediatrics, University of Jos, Jos University Teaching Hospital, Jos, Nigeria
- Fidelia Bode-Thomas Department of Paediatrics, University of Jos, Jos University Teaching Hospital, Jos, Nigeria
- Udochukwu Michael Diala Department of Paediatrics, University of Jos, Jos University Teaching Hospital, Jos, Nigeria
- Christopher Sabo Yilgwan Department of Paediatrics, University of Jos, Jos University Teaching Hospital, Jos, Nigeria
- Isa Abdulkadir Neonatal Unit, Department of Paediatrics, Ahmadu Bello University/Teaching Hospital, Zaria, Nigeria
- Laila Hassan Neonatal Unit, Department of Paediatrics, Ahmadu Bello University/Teaching Hospital, Zaria, Nigeria
- Fatima Abdullahi Neonatal Unit, Department of Paediatrics, Ahmadu Bello University/Teaching Hospital, Zaria, Nigeria
- Zubaida I. Farouk Department of Paediatrics Bayero University, Kano/Aminu Kano Teaching Hospital, Kano, Nigeria
- Idris Yahaya Muhammed Department of Chemical Pathology, Bayero University, Kano/Aminu

EGYPT:

- Dina M. Akmal Department of Pediatrics, Cairo University Children Hospital, Cairo, Egypt
- Dalia A. Khairy Department of Pediatrics, Cairo University Children Hospital, Cairo, Egypt

INDONESIA:

- Radhian Amandito Neonatal Intensive Care Unit, Pondok Indah General Hospital, South Jakarta, DKI Jakarta, Indonesia
- Marcelina Heidy Limanto Neonatal Unit Dr. Cipto Mangunkusumo, Jakarta, Indonesia
- Rosida Sihombing Neonatal Unit Budi Asih District Hospital, Indonesia
- Meilharty Bahar Zulkifli Neonatal Unit Budi Asih District Hospital, Indonesia
- Dewi Iriani Neonatal Unit Koja General Hospital, Jakarta, Indonesia
- Opy Dyah Paramita Neonatal Unit Tarakan General Hospital, Jakarta, Indonesia
- Ellen Sianipar Neonatal Unit Pasar Rebo General District Hospital, Jakarta, Indonesia
- Rocky Wilar Neonatal Unit Prof. Dr. RD Kandou Hospital, Manado, Indonesia
- Johnny Rompis Neonatal Unit Prof. DR. RD Kandou Hospital, Manado, Indonesia
- Magdalena Kristi Daradjati Saudale Neonatal Unit WZ Johannes General Hospital, Kupang, Indonesia
- Woro Indri Padmosiwi Purba Neonatal Unit WZ Johannes General Hospital, Kupang, Indonesia
Kano Teaching Hospital, Kano, Nigeria

• Shehu Umár
Department of Paediatrics, Bayero University, Kano/Aminu Kano Teaching Hospital, Kano, Nigeria

• Abdussalam Muhammed
Department of Paediatrics Bayero University, Kano/Aminu Kano Teaching Hospital, Kano, Nigeria

• Fatima Tsiga-Ahmed
Department of Community Medicine, Bayero University Kano/Aminu Kano Teaching Hospital, Kano, Nigeria.

• Laila Umár
Department of Paediatrics, Murtala Muhammed Specialist Hospital, Kano, Nigeria

VIET NAM:

• Nguyễn Thụy Duong
Newborn Department, Saint Paul Hospital, Hanoi, Viet Nam

• Vũ Thị La
Vinh Phuc Obgyn & Pediatrics Hospital, Vinh Phuc province, Viet Nam

• Khuat Thanh Bình
Pediatrics Department, Moc Chau Referral General Hospital, Son La, Viet Nam

• Nguyễn Thị Kim Ngoc
Pediatrics Department, Ninh Binh Obgyn & Pediatrics Hospital, Ninh Bin, Viet Nam

• Nguyễn Thị Kim Ngoc
Pediatrics Department, Ninh Binh Obgyn & Pediatrics Hospital, Ninh Bin, Viet Nam

• Nguyễn Thị Luyen
Newborn Department, Quang Tri Provincial General Hospital, Quang Tri, Viet Nam

• Vũ Thị Hao
Newborn Department, Vietnam Sweden Hospital, Quang Ninh province, Viet Nam.

Data availability

The full study protocol can be available as supplementary material.

Dr. Coda Zabetta had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Conflicts of Interest

Dr. Tiribelli is the President and CEO of Bilimetrix s.r.l. and Drs. Greco and Coda Zabetta are employees of Bilimetrix s.r.l. In addition, Dr. Tiribelli and Dr. Coda Zabetta have a patent IT 201600094056 pending, a patent IT 201600094078 pending, and a patent PCT/IB2017/05657 pending. The other authors declare no conflicts of interest.

References

[1] Smithnerman H, Stark AR, Bhutani VK. Early recognition of neonatal hyperbilirubinemia and its emergent management. Semin Fetal Neonatal Med 2006;11:214–24.

[2] NICE National Institute for Health and Care Excellence. Neonatal jaundice. [published online May]. https://www.nice.org.uk/guidance/cg98/evidence/full-guideline-245411821; 2010.

[3] Barrington DKJ, Sankaran K, Canadian Paediatric Society Fetus and Newborn Committee. Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks' gestation) – summary. Paediatr Child Health 2007;12:401–7.

[4] World Health Organization. Pocket book of Hospital Care for Children: guidelines for the management of common childhood illnesses. World Health Organization; 2013.

[5] Subcommittee on Hyperbilirubinemia Management of Hyperbilirubinemia in the newborn infant 35 or more weeks of gestation, Pediatrics 2004;114:297–316.

[6] AAP Subcommittee on Neonatal Hyperbilirubinemia. Neonatal jaundice and kernicterus. Pediatrics 2001;108:765–5.

[7] Bhardwaj K, Locke T, Biringer A, et al. Newborn bilirubin screening for preventing severe hyperbilirubinemia and bilirubin encephalopathy: a rapid review. Curr Pediatr Rev 2017;13:67–90.

[8] Ives NK. Management of neonatal jaundice. Paediatr Child Health 2011;21:270–6.

[9] Rama Chandran A. Neonatal hyperbilirubinemia. Paediatr Child Health 2016;26:162–8.

[10] Le Pichon J-B, Riordan SM, Watchko J, Shapiro SM. The neurological sequelae of neonatal hyperbilirubinemia: definitions, diagnosis and treatment of the kernicterus spectrum disorders (KSDs). Curr Pediatr Rev 2017;13:199–209.

[11] Bhutani VK, Johnson L. kernicterus in the 21st century: frequently asked questions. J Perinatol 2009;29(Suppl. 1):S20–4.

[12] Greco C, Arnoldo G, Boo N-Y, et al. Neonatal jaundice in low- and middle-income countries: lessons and future directions from the 2015 Don Ostrow Trieste yellow retreat. Neonatology 2016;110:172–80.

[13] Antionca Huynhate PT, Fajuelo Travezalo MJ, Coreia M, et al. Diagnostics barriers and innovations in rural areas: insights from junior medical doctors on the frontlines of rural care in Peru. BMC Health Serv Res 2015;15:454.

[14] Oluwanso BY, Ogunesi TA, Shusser TM. Why is kernicterus still a major cause of death and disability in low-income and middle-income countries? Arch Dis Child 2014;99:1171–21.

[15] Coda Zabetta CD, Iskander IF, Greco C, et al. Bilistick: a low-cost point-of-care system to measure total plasma bilirubin. Neonatology 2013;103:177–81.

[16] Greco C, Iskander IF, Akmal DM, et al. Comparison between Bilistick System and transcutaneous bilirubin in assessing total bilirubin serum concentration in jaundiced newborns. J Perinatol 2017;37:1028–31. https://doi.org/10.1093/jp/jpx179.4 [published online June 15].

[17] Ben MD, Gazzin S, Tiribelli C. Neonatal hyperbilirubinemia. Ital J Pediatr 2014;40: A10.

[18] Oluwanso BY, Ogunesi TA, Kumar P, et al. Management of late-preterm and term infants with hyperbilirubinemia in resource-constrained settings. BMC Pediatr 2015;15:39.

[19] Arnolda G, Nwe HM, Trevisanuto D, et al. Risk factors for acute bilirubin encephalopathy on admission to two Myanmar national paediatric hospitals. Matern Health Neonatol Perinatal 2015;1. https://doi.org/10.1186/s40748-015-0024-3.

[20] Bossuyt PM, Reitsma JB, Bruins DE, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ 2015;352:351.

[21] Cohen JF, Korevaar DA, Altman DG, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open 2016;6:e012799.

[22] Bhutani VK, Gourley GR, Adler S, Kreamer B, Dalin C, Johnson LH. Noninvasive measurement of total plasma bilirubin. Neonatology 2013;103:177–81.

[23] El-Beshbishi SN, Shattuck KE, Mohammad AA, Petersen JR. Hyperbilirubinemia and transcutaneous bilirubinometry. Clin Chem 2009;55:1280–7.

[24] Okwundu CI, Uthman OA, Suresh G, Smith J, Wiysonge CS, Bhutani VK. Transcutaneous bilirubinometry versus total serum bilirubin measurement for newborns. Cochrane database of systematic reviews. John Wiley & Sons, Ltd.; 2017. https://doi.org/10.1002/14651858.CD012690.

[25] Carstensen B. Comparing clinical measurement methods: A practical guide. John Wiley & Sons; 2011.

[26] Shusser TM, Zamora TG, Appiah D, et al. Burden of severe neonatal jaundice: a systematic review and meta-analysis. BMJ Paediatr Open 2017;1:e000151.31

[27] Walters SJ. Consultants’ forum: should post hoc sample size calculations be done? Pharm Stat 2009;8:163–9.